There are several MAJOR milestones that any Biotech Company hopes to achieve. Beginning enrolling and treating patients in an FDA Phase 1/Phase 2 Clinical Trial of a Key Cancer Drug is definitely high up on the list of MAJOR accomplishments for a Biotech company.
OXIS International (OTCQB: OXIS) Announced this morning that the company has begun enrolling and treating patients in FDA Phase 1/Phase 2 Clinical Trial of Key Cancer Drug OXS-1550!
“This is a very important milestone for Oxis,” said Anthony Cataldo, Chairman and Chief Executive Officer of Oxis. “Moving forward with enrollment of patients will allow us to continue our momentum in the Oxis OXS-1550 Phase 1/Phase 2 FDA trial.”
OXS-1550 (DT2219ARL) is designed to target cancer cells and destroy them, while leaving healthy cells alone. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed.
According to Dr. Daniel Vallera the scientist that developed OXS-1550 and member of the Scientific Advisory Board of OXIS states “We believe OXS-1550 to be a powerful alternative to existing chemotherapies, since many patients fail chemotherapy or reach the toxic limits of their therapy,” Vallera said. “I am looking forward to helping to guide Oxis into the future of targeted immunotherapy.”